Entrada Therapeutics (TRDA) Cash from Operations (2020 - 2026)

Entrada Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 41695000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 8.28% year-over-year to 41695000.0; the TTM figure through Mar 2026 stood at 131700000.0 (down 141.45% YoY), while the FY2025 annual figure was 128512000.0, down 209.24% from the prior year.
• Cash from Operations for Q1 2026 stood at 41695000.0, down from 32203000.0 in the prior quarter.
• The five-year high for Cash from Operations was 203399000.0 in Q1 2023, with the low at 41695000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 27304000.0 (2022), against an average of 9749823.53.
• The sharpest annual moves came in 2023 and 2024: Cash from Operations jumped 1068.98% in 2023, then slumped 687.57% in 2024.
• Entrada Therapeutics' Cash from Operations stood at 27304000.0 in 2022, then jumped by 85.3% to 4013000.0 in 2023, then plunged by 687.57% to 31605000.0 in 2024, then decreased by 1.89% to 32203000.0 in 2025, then slipped by 29.48% to 41695000.0 in 2026.
• Business Quant data shows TRDA's Cash from Operations at 41695000.0 in Q1 2026, 32203000.0 in Q4 2025, and 28313000.0 in Q3 2025.